NCT04577625

Brief Summary

This study evaluates the effect of L. reuteri ATCC PTA 6475 supplementation on testosterone in men.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 8, 2020

Completed
28 days until next milestone

Study Start

First participant enrolled

November 5, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 5, 2021

Completed
Last Updated

June 21, 2021

Status Verified

September 1, 2020

Enrollment Period

7 months

First QC Date

September 30, 2020

Last Update Submit

June 18, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Concentration of total testosterone

    Change in total testosterone concentration over time

    Baseline, 6 weeks, 12 weeks

Secondary Outcomes (3)

  • Free testosterone index

    Baseline, 6 weeks, 12 weeks

  • Percentage of hematokrit

    Baseline, 6 weeks, 12 weeks

  • Number of adverse events

    Continously 12 weeks

Study Arms (3)

L. reuteri Low Dose

ACTIVE COMPARATOR

L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.

Dietary Supplement: Lactobacillus reuteri (L. reuteri)

L. reuteri High Dose

ACTIVE COMPARATOR

L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.

Dietary Supplement: Lactobacillus reuteri (L. reuteri)

Placebo

PLACEBO COMPARATOR

The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.

Dietary Supplement: Lactobacillus reuteri (L. reuteri)

Interventions

L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only

L. reuteri High DoseL. reuteri Low DosePlacebo

Eligibility Criteria

Age50 Years - 65 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Willing and able to give signed informed consent for participation in the study.
  • Healthy males aged between 50-65 with no known underlying medical conditions
  • Subjects who are capable of taking themselves to testing centre at 3 separate timepoints (Baseline, week 6 and week 12).
  • Subjects who are available to give fasting blood samples before 10am on day of blood sample collection
  • No history of androgen or testosterone supplementation within 6 months prior to study start.
  • Subjects who have not been taking antibiotics or probiotic supplements 4 weeks prior to study start 8. Able and willing to comply with the restirictions defined for the study period
  • Ability to understand and comply with the requirements of the study, as judged by the investigator physician

You may not qualify if:

  • Subjects who presently have or have had cardiovascular issues in the past 2 years.
  • Subjects who have a Body Mass Index of \< 18 or \> 30
  • Known elevated Prostate Specific Antigen levels.
  • History of prostate or testicular cancer.
  • Nicotine abuse
  • Alcohol abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Health & Society, Malmö University

Malmo, Skåne County, 205 06, Sweden

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 30, 2020

First Posted

October 8, 2020

Study Start

November 5, 2020

Primary Completion

June 5, 2021

Study Completion

June 5, 2021

Last Updated

June 21, 2021

Record last verified: 2020-09

Locations